Walter Reith

University of Geneva — Switzerland

Immunology and Microbiology · Life Sciences

71h-index18.3kcitations218works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(90), Immune Cell Function and Interaction(90), Immunotherapy and Immune Responses(76), Immunodeficiency and Autoimmune Disorders(32), Immune Response and Inflammation(23)

Publications218 total

Major Histocompatibility Complex Class II Deficiency
Elsevier eBooks·2024
146P A novel allosteric oral immunotherapy small molecule modulates adenosine 2a receptor signaling and restores anti-tumor immune responses
Immuno-Oncology Technology·2023Open Access
Figure S2 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S5 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S4 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S3 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Supplementary Tables from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S5 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S3 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Data from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S4 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S1 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Data from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Supplementary Tables from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S2 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S6 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S6 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Figure S1 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
2023Open Access
Data from Ag-Presenting CpG-Activated pDCs Prime Th17 Cells That Induce Tumor Regression
2023Open Access
Supplemental Information from Ag-Presenting CpG-Activated pDCs Prime Th17 Cells That Induce Tumor Regression
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Bernard Mach(13), Emmanuèle Barras(10), Bénédicte Durand(8), A. Fontana(7), Viktor Steimle(6), Stéphanie Hugues(6), Tobias Suter(6), Hans Acha‐Orbea(6), Salomé LeibundGut‐Landmann(5), Jean‐Marc Waldburger(5), Krzysztof Masternak(5), Isabelle Dunand-Sauthier(4), L. Otten(3), Annick Mühlethaler‐Mottet(3), Madeleine Zufferey(3), Adrià-Arnau Martí i Líndez(3), Magali Irla(3), Aouatef Ait‐Lounis(3), Michel Kobr(3), Juan Dubrot(2)